Skip to main content

Table 1 Antiemetic regimens in each study

From: Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Antiemetic   Day 1 Day 2 Day 3 Day 4
Study 1
 5HT3RA i.v.    
 Aprepitant p.o. 125 mg 80 mg 80 mg  
 Dexamethasone* i.v. 4.95 mg    
 Olanzapine p.o. 5 mg 5 mg 5 mg 5 mg
Study 2
 Granisetron i.v. 1 mg    
 Aprepitant p.o. 125 mg 80 mg 80 mg  
 Dexamethasone**
 or
 Dexamethasone
p.o. 12 mg    
i.v. 9.9 mg    
 Olanzapine p.o. 5 mg 5 mg 5 mg 5 mg
Study 3
 Granisetron i.v. 1 mg    
 Dexamethasone **
 or
 Dexamethasone
p.o. 12 mg 8 mg 8 mg  
i.v. 9.9 mg 6.6 mg 6.6 mg  
 Olanzapine p.o. 5 mg 5 mg 5 mg 5 mg
  1. Dexamethasone 3.3 mg i.v. = 4 mg p.o.
  2. ※Granisetron: 1 or 3 mg, palonosetron: 0.75 mg, ramosetron: 0.3 mg.
  3. *When paclitaxel is used, 9.9 or 12 mg DEX is, respectively, administered intravenously or orally on day 1
  4. **When more than 135 mg/m2 paclitaxel is used, 19.8 or 20 mg DEX is, respectively, administered intravenously or orally on day 1
  5. 5-HT3RA 5-hydroxytryptamine-3 receptor antagonist.